Bioequivalence study of 500 mg glucosamine sulfate in Thai healthy volunteers

Journal of the Medical Association of Thailand

Volumn 92, Issue 9, 2009, Pages 1234-1239

  Akarasereenont, Pravit ^a   Chatsiricharoenkul, Somruedee ^a   Pongnarin, Piyapat ^a   Sathirakul, Korbtham ^b   Kongpatanakul, Supornchai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Bioequivalence; Glucosamine; Liquid chromatography mass spectrometry; Pharmacokinetics

Indexed keywords

FLEXSA; GLUCOSAMINE SULFATE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIARTRIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY MASS; CLINICAL LABORATORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ELECTROLYTE BLOOD LEVEL; FEMALE; HEART PALPITATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CROSS-OVER STUDIES; FEMALE; GLUCOSAMINE; HUMANS; MALE; THAILAND; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 70349266028     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Reginster JY, Richy F, Bruyere O. Glucosamine as a pain-modifying drug in osteoarthritis. What's new in 2006. Rev Med Liege 2006; 61: 169-172
2. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005; 43: 187-201.
3. Matheson AJ, Perry CM. Glucosamine: a review of its use in the management of osteoarthritis. Drugs Aging 2003; 20: 1041-1060 (Pubitemid 37549879)
4. Hungerford MW, Valaik D. Chondroprotective agents: glucosamine and chondroitin. Foot Ankle Clin 2003; 8: 201-219
5. D'Ambrosio E, Casa B, Bompani R, Scali G, Scali M. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981; 2: 504-508 (Pubitemid 11143940)
6. Institute of Medicine and National Research Council of the National Academies. Prototype monograph on glucosamine. In: Dietary supplements: a framework for evaluating safety. C1-C86. Washington, DC: Institute of Medicine and National Research Council of the National Academies; 2004: 1-97.
7. Houpt JB, McMillan R, Wein C, Paget-Dellio SD.Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 2423-2430 (Pubitemid 29528986)
8. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man [abstract]. Arzneimittelforschung 1993; 43: 1109-1113
9. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung 2001; 51: 699-725. (Pubitemid 32889393)
10. Blume HH, Midha KK. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1993; 82: 1186-1189 (Pubitemid 24004457)
11. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: statistical approaches to establishing bioequivalence. Washington, DC: HHS/FDA/CDER; 2001.